Neuphoria Therapeutics Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Neuphoria Therapeutics Inc. (NEUP) reported Revenue from Contract with Customer, Excluding Assessed Tax of $15.65 million for the 12-month period ending 2025-06-30, per its 10-K filed 2025-09-29.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-05-15
- Neuphoria Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was -$13.27K.
- Neuphoria Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $15.00M.
- Neuphoria Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-12-31 was $662.72K.
- Neuphoria Therapeutics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $15.65M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-06-30 | -$13.27K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $14.99M derived: sum of 2 quarters · filed 2026-05-15 | $15.65M derived: sum of 3 quarters · filed 2026-05-15 | $15.65M 10-K · filed 2025-09-29 |
| 2025-03-31 | $15.00M 10-Q · filed 2026-05-15 | $15.66M derived: sum of 2 quarters · filed 2026-05-15 | $15.66M 10-Q · filed 2026-05-15 | |
| 2024-12-31 | $662.72K 10-Q · filed 2026-02-17 | $662.72K 10-Q · filed 2026-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |